← All trials
NCT06866613
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 31, 2025
- Primary completion
- Oct 18, 2025
- Completion date
- Oct 30, 2025
- First posted
- Mar 10, 2025
- Last posted
- Nov 26, 2025
- Enrollment
- 69
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Teikoku Seiyaku Co., Ltd.Lead sponsor
- Teikoku Seiyaku Co., Ltd.Official
- SocraMetrics GmbHCollaborator
- CRM Biometrics GmbHCollaborator
- SocraTec R&D GmbHCollaborator
- ClinSearch, LLCCollaborator
- HWI pharma services GmbHCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.